A subsequent subgroup analysis focusing on younger patients (age ≤ 60) revealed that patients with ABC-DLBCL of the MCD and N1 subtypes experienced a notable 3-year EFS and OS rate of 100% when treated with ibrutinib plus R-CHOP, in contrast to 42.9% and 50%, respectively, in the R-CHOP-alone arm [82]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.